NVE (NVEC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Jun, 2026Executive summary
Annual meeting scheduled for August 6, 2026, at 3:30 PM CDT in Eden Prairie, Minnesota.
Shareholders are encouraged to review proxy materials and vote by August 5, 2026.
Voting matters and shareholder proposals
Election of seven directors is on the agenda, with board recommendations for all nominees.
Advisory vote on named executive officer compensation is included.
Ratification of Boulay PLLP as independent auditor for fiscal year ending March 31, 2027.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Director nominees: Daniel A. Baker, Peter G. Eames, Terrence W. Glamer, Patricia M. Hollister, James W. Bracke, Kelly Wei, and Carolyn W. Valentine.
Partial view of Summaries dataset, powered by Quartr API
Latest events from NVE
- Shareholders will vote on directors, executive pay, and auditor ratification at the 2026 meeting.NVEC
Proxy filing22 Jun 2026 - Leadership transitions and robust growth mark a year of expansion and innovation.NVEC
Proxy filing22 Jun 2026 - Board expansion, executive pay, and auditor ratification headline the August 2026 proxy.NVEC
Proxy filing22 Jun 2026 - Quarterly net income rose 27% year-over-year, driven by strong product sales and margin gains.NVEC
Q4 20267 May 2026 - Quarterly revenue up 23% and net income up 11%, with a $1.00 dividend announced.NVEC
Q3 202614 Apr 2026 - Revenue and net income declined, but gross margin and cash returns to shareholders remained strong.NVEC
Q1 20253 Feb 2026 - Gross margin rose to 86% as R&D revenue surged and a $1.00 dividend was declared.NVEC
Q2 202519 Jan 2026 - Revenue and net income fell, but gross margin improved to 84% and a dividend was declared.NVEC
Q3 20259 Jan 2026 - Maintained strong earnings, expanded R&D, and appointed a new director with medical expertise.NVEC
Proxy Filing1 Dec 2025